Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Over recent months share price is moving in the right direction. (for me I am long)

I think it is going to continue its uptrend at a more rapid speed.



News Article
Appointment of distributor for HypoSalix
05/10/2006
London, UK, 5 October 2006: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company, is pleased to announce a new distributor for its recently registered artificial saliva spray, HypoSalix.
DEM Pharmaceuticals in Istanbul, Turkey have been appointed BioProgress's official distributor of Hyposalix for Turkey. The agreement is managed through BioProgress"s French operation, Dexo SA. The terms of the agreement are not disclosed
Hyposalix is a medical device for the treatment of xerostomia, and a key element in the BioProgresss strategy of developing products for its Patient Supportive Care franchise.
Steve Martin, Chief Development Officer, BioProgress, said:
"The licensing of HypoSalix to a partner is a key milestone in BioProgresss commercialisation strategy of its products. HypoSalix has been recently registered and received a great deal of interest world wide. Turkey is an important and fast growing market and we believe that DEM Pharmaceuticals will be a solid partner in marketing our Patient Supportive Care franchise.
For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEOSteve Martin, CDO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

Hmm Fred, it's a pity it takes them 13 days to email the RNS's to registered people! I got that this morning too but read it on MAM on 5th October.

No problem though, the chart is behaving extremely positively while we await some developments. Big resistance area coming up. The range from 58p to 70p has always been an active area between buyers and sellers.

Yep, +/-60p the biggie, Bones

Interesting close today Bones. ;-)))

Yes, Big Al. Another last 1/2 hour flurry which has been the pattern all week. When the interims came out, Mr Private Investor was nowhere to be seen but the CEO has done the rounds with the City boys in the last two weeks. I would think there has been some institutional buying to cause these daily 2 or 3 point tick ups. It's been orderly and no sign of hysteria...........so far! Long may it continue

And so it continues to tick up

A surprise Xmas present is rumoured to be on its way from R. Trevellion. The guy delivers, so it could be very nice.

With some positive product news, BPRG has performed well over the last 6 months. The products have real mass market potential.

A little info which you may not be aware of:-

BioProgress at Arab Health 2007

25/01/2007

London, UK, 25 January 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare announces that it will be showing its technologies and products at Arab Health, Dubai on 29 January - 01 February.

Arab Health is attended by over 33,000 visitors with 2,200 exhibiting companies. With many of the global and regional pharmaceutical companies attending, Arab Health 2007 offers BioProgress a central forum targeting a global audience. We plan to extend our strategic relationships, and target additional distributors for our current portfolio of over 40 pharmaceutical and healthcare products, and five commercialised enabling systems.

For more details on Arab Health 2007, visit www.arabhealthonline.com.

Steve Martin, Chief Development Officer said:

"Arab Health is an important forum to show our products and technologies to a wide global audience. This is the first time we have shown at Arab Health and represents a significant step forward for the company where we are showcasing over 40 products, and a range of unique enabling drug delivery systems.

For further information:

BioProgress Plc

+ 44 (0) 20 7098 9881
kim

Looks a bit toppy to me.

;-)

Ignore Al .... wind up merchant

:-)

News Article
Operational Board Update and Appointment

01/02/2007

London, UK, 1 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, today announces the creation of a new executive operational board for the Company, and the appointment of Keith Hemming, as Head of Operations, a new position within the management team of BioProgress.

The operational board will be responsible for the day to day management of the Group. This has become necessary as the number of new development projects both for partners and for the Company's own pharmaceutical division is increasing substantially due to positive validation work and the adoption of a number of BioProgress"s enabling systems. At the same time the core pharmaceutical division Dexo is undergoing rapid growth in all of its territories. This underlying organic growth validates the Companys product led strategy and creates the resource necessary for continued substantial growth.

Keith Hemming, the new Head of Operations, has over twenty years experience in the Pharmaceutical industry, holding senior marketing and General Management positions with Squibb, Yamanouchi, and most recently as President UK Operations for Fujisawa Pharma, member of the Fujisawa European senior management team. Prior to this he was with Astellas Pharmaceuticals Global Licensee Division working on European strategy and implementation. During his career he launched Flomax and Protopic in the UK, and took Prograf, an immunosuppressant, to market leadership.

Keith was a member of the Board of Management of the Association of British Pharmaceutical Industry (ABPI) for four years, and member of the UK Pharmaceutical Code of Practice Appeal Board.

He was also founder and first Chair of the UK Japanese Pharmaceutical Group associated to the Japanese Pharmaceutical Manufacturers Association (JPMA), and Chair of the Industry Group for the National Health Service Framework for Renal Services.

Richard Trevillion, Chief Executive Officer, BioProgress Plc, said:

"We are pleased to welcome Keith to the operational management team. Keith has substantial experience in sales and marketing and in managing high growth late stage pharmaceutical product development. His knowledge of the Japanese pharmaceutical industry is also welcome as BioProgress increases its marketing activity within Japan.

Keith Hemming, Head of Operations, said:

I am delighted to be joining BioProgress at such an exciting stage in the Companys development. The recent increase in activity is testament to the strength of the core enabling systems which are contributing to a strong product development pipeline. The resulting rapid growth in the Dexo pharmaceutical sales and marketing division validates the product led speciality pharmaceutical model that BioProgress is proactively pursuing.

This company seems to be heading in the right direction at last.
kim

BioProgress PLC
07 March 2007

For Immediate Release

BioProgress plc

BioProgress (DEXO) Agreement to Promote Accuhist(R) Product Line in U.S.

London, UK, 7 March 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, is
pleased to announce the completion of an agreement with Tiber Laboratories to
promote the Accuhist(R) line of pediatric drops throughout the United States.

The company will be responsible for sales and promotion of three well-known
products - Accuhist Pediatric Drops, Accuhist(R) PDX Drops, and Accuhist(R) DM
Drops. The products compete in the growing category of cough/cold drops for
infants, a market currently in excess of $2 billion. The Accuhist(R) line was
sold nationally by PediaMed in the years prior to the sale to Tiber
Laboratories. In recent years the Accuhist(R) line held the number two position
in share of the key US market. The new agreement between Tiber Laboratories and
DEXO, BioProgress' U.S. pharmaceutical subsidiary, will reestablish promotion of
this widely prescribed product.

In addition, BioProgress will develop for Tiber Laboratories a film strip
version of the popular Accuhist(R) product which is scheduled for launch in H2
2007. The product will be promoted by Tiber Laboratories with a development
royalty on sales paid to BioProgress' manufacturing subsidiary BioTec Films.
The tremendous growth of film strips as a convenient means of patient dosing is
changing the face of medicine, and Tiber Laboratories anticipates the film strip
becoming an integral part of their product offering.

Specifically, BioProgress will realise 50% of the sales of the Accuhist(R)
Pediatric, PDX and DM drops for a period beginning shortly after the date of
this agreement and a further 10% Royalty based on gross sales of the film strip
version of Accuhist(R). BioProgress will also have the opportunity to realize up
to 80% of the sales of Accuhist(R) Pediatric, PDX and DM drops once various
milestones have been achieved regarding the sales of the film strip product.

BioProgress continues the aggressive development of products for the pediatric
market. This agreement adds pediatric drop products to the portfolio,
augmenting the existing array of products including brands such as Ah-Chew(R)
and E-Z Spacer(R). The company has several new products in development
including an orally dissolving tablet, and several films version of the Ah-Chew
line.

Richard Trevillion, Chief Executive Officer, of BioProgress commented:

'The Accuhist(R) line is a high profile U.S. brand that will add depth to our
growing U.S. portfolio. The Accuhist(R) product is a prominent player in the
pediatric drops category over the last several years, and we look forward to
adding DEXO's sales resources to increase the Accuhist share of this major
category.'

For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a vertically integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL(TM) polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com

About Tiber Laboratories, LLC

Tiber Laboratories LLC is a Georgia, USA corporation focused on the development
and distribution of prescription products to the pediatric and primary care
markets. The therapeutic focus of Tiber Laboratories has been in the areas of
respiratory management and dermatology. However, there are other markets
currently under consideration. Tiber is lead by a team of highly experienced
industry veterans. They have been active in the acquisition of several
recognized brands including the Accuhist(R), Endal(R), Histex(TM), and
Viravan(TM). Tiber will be launching several new products through their own
sales forces as well as through partnership.


BioP is a transformed company and is going about it's business quietly; building an interesting product base and portfolio. RT doing a good job. Preliminary year end results due on the 19 April. Long awaited news of a big pharma deal cant be far away! Keep an eye on them.

Good News Today?

Walrus

Actually, that was a mindless post to see if my sign on worked.

That said I do expect significant news in the short term. All one has to do is go backwards from a product launch last qtr 2007 and BPRG simply have to have news in the wing.

Walrus

ttt

;-0

Not the result some wanted, but with a mkt cap of around 90m and less than zero profits, what else can be expected?

They haven't given us a product buy for EXGEL and really for most of us that's what we have been led to believe was the lynchpin for the future? Mkt cap might halve from here and not many would be surprised? 'Till they give us the nod on XGEL that is.

What happened to the millions of rampers who use to call me all sorts of names on the bprg threads ?

Did they all go bust ?

No Dill bought at 28p and holding, and holding. I think there is lot further to go!








And it is up 8-)


Nos dda i chwi.